参与物
| 角色 | 名称 | HCID | 投料 |
|---|
| 反应物 | 1,3-dimethyl-1H-pyrazol-4-amine | HCID 4431056 | — |
| 反应物 | 6-Chloro-4-[(2-methyl-1-oxo-3,4-dihydroisoquinolin-8-yl)amino]pyridine-3-carbonitrile | HCID 86655132 | — |
| 试剂 | 碳酸氢铯 | HCID 10796 | — |
| 催化剂 | 4,5-双二苯基膦-9,9-二甲基氧杂蒽 | HCID 636044 | — |
| 催化剂 | 醋酸钯 | HCID 4144353 | — |
| 溶剂 | 1,4-二氧六环 | HCID 31275 | — |
| 产物 | 6-[(1,3-Dimethylpyrazol-4-yl)amino]-4-[(2-methyl-1-oxo-3,4-dihydroisoquinolin-8-yl)amino]pyridine-3-carbonitrile | HCID 44609354 | 7.33% |
反应步骤
6-chloro-4-(2-methyl-1-oxo-1,2,3,4-tetrahydroisoquinolin-8-ylamino)nicotinonitrile (595 mg, 1.90 mmol), Palladium(II) acetate (34.2 mg, 0.15 mmol), 9,9-Dimethyl-4,5-bis(diphenylphosphino)xanthene (132 mg, 0.23 mmol), 1,3-dimethyl-1H-pyrazol-4-amine (423 mg, 3.80 mmol) and Cesium carbonate (744 mg, 2.28 mmol) were suspended in dioxane (40 mL). The reaction was purged for 5 mins with nitrogen and then heated to 90 °C for 2 hour with stirring. The reaction was cooled to RT. The crude product was purified by ion exchange chromatography, using an SCX column. The desired crude product was eluted from the column using 7M NH3/MeOH and fractions were evaporated to dryness to afford crude product .The crude product was purified by preparative basic HPLC. Fractions containing the desired compound were evaporated to dryness to afford 6-(1,3-dimethyl-1H-pyrazol-4-ylamino)-4-(2-methyl-1-oxo-1,2,3,4-tetrahydroisoquinolin-8-ylamino)nicotinonitrile (54.0 mg, 7.33 %) as a beige solid.
来源与证据
| 来源数据集 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-2e4132c3c32149d3a68cd64301eacce5 |
|---|
| 来源说明 | 750 AstraZeneca ELN dataset |
|---|